Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1008)	11/9/1998 2:55:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 1722

11/09 12:00 Positive results on [Centocor's] arthritis drug reported By Mark Egan LOS ANGELES, Nov 9 (Reuters) - A drug already being used to treat Crohn's disease, an inflammation of the bowel, also reduces symptoms and pain in rheumatoid arthritis patients, researchers said on Monday. Researchers said that the drug infliximad, made by Centocor Inc <CNTO.O>. and marketed under the brand name Remicade, reduced pain and symptoms of the chronic joint condition by 52 percent in patients receiving the drug compared to those not taking it. More than 2.5 million Americans suffer from rheumatoid arthritis, one of the most severe forms of the disease. Results of the phase III trial of 428 patients, usually the last step before a drug seeks regulatory approval, were presented at the American College of Rheumatology conference in San Diego. The trial, which followed the effects of Remicade when taken in conjunction with the standard drug methotrexate, revealed that 52 percent of patients experienced at least a 20 percent drop in inflammation and pain. About 28 percent of patients showed a 50 percent decrease in inflammation and pain with 12 percent experiencing a 70 percent improvement. "We were really struck by the really positive outcome of this trial," Dr. Peter Lipsky, of the University of Texas Southwestern Medical Center in Dallas and a principal investigator in the trial told Reuters. "What struck us the most was that all doses that we tested were effective and even the lowest dose (3mg/kg) that was tested was comparably effective as all the others." If approved, patients may find the drug, which is given intravenously once every eight weeks, more convenient to use that the recently approved rheumatoid arthritis drug Enbrel which has to be self-injected twice a week, Lipsky said. "In general the trial results look pretty much comparable (with Enbrel)," Lipsky said. "The major issue is convenience -- whether or not the patients would choose to have subcutaneous medicine twice a week or intravenous medicine one every eight weeks." The drug may also be cheaper than Enbrel, which is made by Seattle-based biotechnology company Immunex Corp <IMNX.O>. Enbrel will cost about $220 a week while analysts expect Remicade will cost between $96 and $156 a week. Remicade is a monoclonal antibody which binds to a protein that is central to inflammation in rheumatoid arthritis, called the tumor necrosis factor, and neutralizes it. All patients in the trial had long-standing rheumatoid arthritis. Lipsky said that he expects the drug will have a more pronounced effect on those with less advanced problems, although further trials would be needed to prove that point. Rheumatoid arthritis occurs when the body's immune system mistakenly turns against the joints. No one knows why this happens but scientists suspect an infection may be to blame. It usually strikes young people between the ages of 20 and 50 and can cripple a person as the joints are destroyed. Centocor said in a statement it will file an application with regulators to approve the drug within the next few months. The U.S. Food and Drug Administration approved Remicade for the treatment of Crohn's disease in August. If approved for rheumatoid arthritis, the drug will compete with Enbrel which was approved by regulators, also for use in conjunction with methotrexate, earlier this month. Enbrel, known generically as etanercept, has been shown to help reduce the symptoms of moderate to severe rheumatoid arthritis. New data on the long-term effects of Enbrel will be presented at the conference later this week.